METHODS OF TREATING OCULAR CONDITIONS

1 - 61 . (canceled)

62 . A method for increasing the amount or concentration of one or more lacrimal proteins produced by an individual in need thereof, comprising local administration of a therapeutically effective amount of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, in alternating nostrils of an individual in need thereof,

wherein the therapeutically effective amount per dose is between 1 microgram and 5 milligrams of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, per dose.

63 . The method of claim 62 , wherein the one or more lacrimal proteins are selected from the group consisting of epithelial growth factor, lactoferin, lacritin, prolactin, adrenocorticotropic, leucine enkephalin, ALS2CL, ARHGEF19, KIAA1109, PLXNA1, POLG, WIPI1, ZMIZ2, or other proteins of the tear proteome.

64 . The method of claim 62 , wherein the pharmaceutically acceptable salt is a citrate salt or a galactarate salt.

65 . The method of claim 64 , wherein the pharmaceutically acceptable salt is (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate or (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine hemigalactarate.

66 . The method of claim 64 , wherein the pharmaceutically acceptable salt is (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine hemigalactarate dihydrate or (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine hemigalactarate monohydrate.

67 . The method of claim 62 , wherein the therapeutically effective amount is between 500 micrograms and 5 milligrams of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, per dose.

68 . The method of claim 62 , wherein the therapeutically effective amount is between 500 micrograms and 3 milligrams of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, per dose.

69 . The method of claim 62 , wherein the therapeutically effective amount is between 1 microgram and 2 milligrams of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, per dose.

70 . The method of claim 62 , wherein the therapeutically effective amount is between 100 micrograms and 1000 micrograms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, per dose.

71 . The method of claim 62 , wherein (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, is administered at least once daily.

72 . The method of claim 62 , wherein (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, is administered at least twice daily.

73 . The method of claim 62 , wherein (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, is administered as a liquid, suspension, aerosol, gel, ointment, dry powder, cream, paste, lotion, or balm.

74 . The method of claim 62 , wherein (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, is administered by a syringe, dropper, bottle nebulizer, atomization pump, inhaler, powder spray device, vaporizer, patch, medicated stick, pipette, or jet of liquid.

75 . The method according to claim 62 , wherein (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, is administered with a medical device.

76 . The method of claim 62 , wherein the (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, is administered in a pharmaceutical formulation for nasal administration comprising between 10 mg/mL and 25 mg/mL of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof.

77 . The method of claim 62 , wherein the (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, is administered in a pharmaceutical formulation for nasal administration comprising between 5 mg/mL and 50 mg/mL of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof.

78 . The method of claim 62 , wherein the (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, is administered in a pharmaceutical formulation for nasal administration comprising about 1 mg/mL, about 5 mg/mL, about 6 mg/mL, or about 10 mg/mL of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof.

79 . The method of claim 62 , wherein the (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, is administered prior to or after LASIK eye surgery.

80 . The method according to claim 62 , wherein the (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, is administered prior to or after an ophthalmologic surgical procedure.